Program Overview

This activity is a result of an international summit meeting of leading HIV treaters and nephrologists held in May 2007. This program offers a comprehensive, updated review of all aspects of renal dysfunction and HIV disease. The activity will summarize current opinion on the interactions of HIV infection and renal disease, including renal complications of HIV/AIDS and its therapies, disease-causative mechanisms, prevention, treatments, and outcomes.

Link for the post test is: www.MSSMTV.org/rhiv.

Target Audience

This activity is intended for health care providers involved in the management of HIV-infected patients.

Educational Objectives

Upon the completion of this program participants will be able to:
•	Describe the risk factors for and impact of renal disease in patients with HIV, including special populations
•	Discuss how to monitor and manage renal function in patients with HIV on antiretroviral therapy
•	Outline management considerations to prevent or minimize the development of renal disease in patients with HIV

Accreditation Statement

The Mount Sinai School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide Continuing Medical Education for physicians.

Credit Designation Statement

The Mount Sinai School of Medicine designates this educational activity for a maximum of 1 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Financial Disclosure Statement

It is the policy of Mount Sinai School of Medicine to ensure objectivity, balance, independence, transparency, and scientific rigor in all CME-sponsored educational activities. All faculty participating in the planning or implementation of a sponsored activity are expected to disclose to the audience any relevant financial relationships and to assist in resolving any conflict of interest that may arise from the relationship. Presenters must also make a meaningful disclosure to the audience of their discussions of unlabeled or unapproved drugs or devices.

•	Jonathan Winston, MD, has received honoraria for speaking lectures and is part of the speakers' bureau for Gilead Sciences, Inc.
•	Jorge Diego, MD, has no financial relationship(s) to disclose.
•	Douglas Dieterich, MD, (independent reviewer) is a consultant/advisor for and has received honoraria from Boehringer Ingelheim, Bristol-Myers Squibb, Gilead Sciences, Inc, Novartis, Roche, Schering-Plough

Media

Internet Activity

System Requirements

Windows
    Windows 2000, ME, XP, Vista
    IE 5.0 or later/Netscape 7/Mozilla 1.5/Opera 7/Firefox
    Flash 7 or later

Macintosh
    OS X
    Safari/Mozilla 1.5/Firefox
    Flash 7 or later

Internet Connection
    Minimum connection of 56Kbps

Privacy Policy

For further information about the Mount Sinai School of Medicine privacy and confidentiality policy, click here: http://www.mountsinai.org/msh/msh_pp.jsp

Copyright

Unless otherwise noted, all documents accessed from this page are viewed as a precious resource of Mount Sinai School of Medicine and are copyright, Mount Sinai School

This program is supported by an independent educational grant from Gilead Sciences Medical Affairs.